Swiss company launches rapid test to determine Covid-19 severity
Septic shock is one of the major complications of Covid-19.
Keystone / Pablo Gianinazzi
Lausanne-based medical technology firm Abionic has created the first rapid blood test to help doctors decide whether Covid-19 patients require treatment in intensive care units.
This content was published on
2 minutes
Keystone-SDA/jdp
Español
es
COVID-19: Prueba rápida suiza detecta gravedad de pacientes
According to a presentationExternal link by Abionic, the Covid-19 Severity Score test uses a small blood sample from the fingertip to determine how serious the disease is and how likely it is to worsen. Physicians receive the test results within five minutes and could then decide whether a patient should be admitted to intensive care, transferred to a general hospital ward or discharged from the hospital.
The test is intended to ease the burden on healthcare workers and intensive care units that are reaching capacity in some countries with high numbers of Covid-19 patients.
Abionic adapted the diagnostics process it developed for the detection of sepsis, a life-threatening complication of bacterial and viral infections, for use in Covid-19 in order to provide faster results. The Covid-19 severity test is based on the “sequential organ failure assessment score” (SOFA score), which is tracked by hospitals to determine a patient’s status in intensive care units based on organ functioning.
“Already in March of this year, we noticed in many different publications that one of the most frequent causes of death in Covid-19 patients was indeed bacterial sepsis,” Abionic CEO Nicolas Durand told Reuters news agency.
The test has been validated in clinical studies involving several hundred patients in various countries and hospitals and has received approval for use in Europe.
Founded in 2010 as a spin-off of the Swiss Federal Institute of Technology Lausanne (EPFL), Abionic distributes its tests and devices mainly in Europe. The company has received almost CHF37 million ($40.7 million) from investors in three rounds of financing.
Popular Stories
More
Swiss Abroad
Ups and downs: Swiss drivers benefit from world’s only mobile bridge
Swiss study: Humans can train their brain to communicate with machines
This content was published on
Humans can learn to share their thoughts with machines according to a new study by researchers at the University of Geneva.
Geneva politician arrested on suspicion of drug trafficking
This content was published on
A local Geneva politician was arrested on Wednesday as part of a major police operation to dismantle an organised drug trafficking ring.
Trade conflict: How Swiss companies are preparing for Trump tariffs
This content was published on
Switzerland has so far been spared tariff threats from the new US President Donald Trump. Nevertheless, Swiss companies are taking precautions.
Economists lower Switzerland’s growth forecast for 2025
This content was published on
Economic experts believe that Switzerland's growth will only be marginally weaker than recently. But GDP is expected to accelerate in 2026.
This content was published on
As money is poured into the search for a silver bullet to Covid-19, some experts warn that the pandemic could also worsen the antibiotics crisis.
The Swiss biotech shaking up the antibiotics model
This content was published on
Family-owned Debiopharm says it’s time to treat the life-saving medicine like insurance if we want to avoid another pandemic.
Intensive care staff exhausted as Covid numbers rise
This content was published on
Intensive care workers are going into the second wave of the coronavirus pandemic exhausted, the Swiss Society of Intensive Care Medicine has warned.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.